The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).
Kathleen Margaret Mahoney
No relevant relationships to disclose
SuChun Cheng
No relevant relationships to disclose
Rupal Satish Bhatt
No relevant relationships to disclose
Mekailah Simpson
No relevant relationships to disclose
Michael B. Atkins
Consultant or Advisory Role - Roche/Genentech
Igor Puzanov
No relevant relationships to disclose
Sabina Signoretti
No relevant relationships to disclose
M Dror Michaelson
Consultant or Advisory Role - Abbott Laboratories (U); AVEO (U); Eisai (U); Millennium (U); Novartis (U); Pfizer (U)
Research Funding - Abbott Laboratories; AVEO; Eisai; Millennium; Novartis; Pfizer
David F. McDermott
Consultant or Advisory Role - Genentech; Pfizer
Toni K. Choueiri
Consultant or Advisory Role - Bayer; GlaxoSmithKline; Pfizer
Research Funding - Pfizer